MANKIND - Swing Trade Analysis with AI Signals
Back to ListSwing Trade Rating: 3.3
| Stock Code | MANKIND | Market Cap | 82,626 Cr. | Current Price | 2,001 ₹ | High / Low | 2,727 ₹ |
| Stock P/E | 46.8 | Book Value | 376 ₹ | Dividend Yield | 0.05 % | ROCE | 15.0 % |
| ROE | 13.9 % | Face Value | 1.00 ₹ | DMA 50 | 2,149 ₹ | DMA 200 | 2,282 ₹ |
| Chg in FII Hold | -1.49 % | Chg in DII Hold | 1.35 % | PAT Qtr | 513 Cr. | PAT Prev Qtr | 459 Cr. |
| RSI | 37.3 | MACD | -11.3 | Volume | 8,52,690 | Avg Vol 1Wk | 5,74,108 |
| Low price | 1,995 ₹ | High price | 2,727 ₹ | PEG Ratio | 5.56 | Debt to equity | 0.47 |
| 52w Index | 0.79 % | Qtr Profit Var | 24.5 % | EPS | 41.3 ₹ | Industry PE | 27.2 |
📊 Mankind Pharma (MANKIND) shows strong fundamentals but weak technicals for swing trading. The RSI at 37.3 indicates oversold conditions, suggesting a possible rebound. However, the MACD (-11.3) reflects bearish momentum, and the stock is trading below both 50 DMA (2,149 ₹) and 200 DMA (2,282 ₹), showing short-term weakness. With a high P/E of 46.8 compared to the industry average of 27.2, the stock appears overvalued. Overall, this is a moderately risky swing trade candidate with limited upside unless momentum improves.
💡 Optimal Entry Price: Around 1,980–2,020 ₹ (near support zone).
📈 Exit Strategy (if already holding): Consider exiting near 2,150–2,200 ₹ (close to 50 DMA resistance) unless momentum strengthens further.
✅ Positive
- Quarterly PAT improved (513 Cr. vs 459 Cr.).
- EPS of 41.3 ₹ reflects earnings strength.
- ROCE (15.0%) and ROE (13.9%) are decent for the sector.
- DII holdings increased (+1.35%), showing domestic investor support.
⚠️ Limitation
- Stock trading below both 50 DMA and 200 DMA.
- Bearish technical indicators (MACD negative, RSI oversold).
- High P/E (46.8) compared to industry average (27.2).
- PEG ratio of 5.56 suggests expensive valuation relative to growth.
- Dividend yield is very low (0.05%).
📉 Company Negative News
- FII holdings decreased (-1.49%), showing reduced foreign investor confidence.
- Stock has dropped sharply from 52-week high (2,727 ₹ to 2,001 ₹).
📈 Company Positive News
- Strong quarterly profit growth (24.5% variation).
- DII support increased, balancing foreign outflows.
- EPS growth supports valuation strength.
🏭 Industry
- Industry PE is 27.2, much lower than Mankind Pharma’s 46.8, suggesting peers are more reasonably valued.
- Pharma sector remains defensive with consistent demand and long-term growth potential.
🔎 Conclusion
Mankind Pharma is a moderately risky swing trade candidate due to bearish technicals and high valuation. Entry near 1,980–2,020 ₹ offers limited risk, but upside is capped around 2,150–2,200 ₹ unless momentum improves. Strong profit growth and domestic investor support provide some confidence, but weak technicals and declining foreign interest make this suitable only for cautious short-term trades.